NRx Pharmaceuticals, Inc.
$3.2
▲
1.85%
2026-04-21 08:28:01
www.nrxpharma.com
NCM: NRXP
Explore NRx Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$105.82 M
Current Price
$3.2
52W High / Low
$3.84 / $1.62
Stock P/E
—
Book Value
$-0.5
Dividend Yield
—
ROCE
103.85%
ROE
146.18%
Face Value
—
EPS
$-1.34
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
29
Beta
1.83
Debt / Equity
-0.04
Current Ratio
0.31
Quick Ratio
0.31
Forward P/E
17.08
Price / Sales
59.93
Enterprise Value
$66.17 M
EV / EBITDA
-4.11
EV / Revenue
54.02
Rating
Strong Buy
Target Price
$38
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | XBiotech Inc. | $2.51 | — | $78.32 M | — | -39.17% | -28.23% | $3.61 / $2.09 | $4.6 |
| 2. | Axsome Therapeutics, Inc. | $184.13 | — | $9.35 B | — | -54.42% | -2.52% | $191.5 / $96.09 | $1.74 |
| 3. | Oragenics, Inc. | $0.71 | — | $3.19 M | — | -113.05% | -2.44% | $9.6 / $0.5 | $1.94 |
| 4. | Candel Therapeutics, Inc. | $7.22 | — | $466.58 M | — | -41.46% | -64.58% | $7.25 / $4.34 | $0.95 |
| 5. | Aprea Therapeutics, Inc. | $0.98 | — | $11.45 M | — | -100.49% | -74.58% | $2.22 / $0.55 | $1.52 |
| 6. | MiNK Therapeutics, Inc. | $12.82 | — | $63.66 M | — | 859.68% | 57.3% | $76 / $6.34 | $-3.02 |
| 7. | CG Oncology, Inc. | $70.4 | — | $6.2 B | — | -25.08% | -21.67% | $73.56 / $19.47 | $9.33 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.98 M | 0.24 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -4.62 M | -4.02 M | -3.73 M | -3.75 M | -2.43 M | — |
| Net Profit | 0.36 M | -5.89 M | -17.58 M | -5.51 M | -9.08 M | — |
| EPS in Rs | 0.01 | -0.18 | -0.53 | -0.17 | -0.27 | -0.15 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.23 M | 0 M | 0 M | 0 M |
| Operating Profit | -16.22 M | -18.5 M | -27.59 M | -44.34 M |
| Net Profit | -28.62 M | -25.13 M | -30.15 M | -39.75 M |
| EPS in Rs | -0.87 | -0.76 | -0.91 | -1.2 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 12.96 M | 3.65 M | 7.32 M | 25.82 M |
| Total Liabilities | 28.89 M | 26.87 M | 19.05 M | 18.41 M |
| Equity | -15.94 M | -23.22 M | -11.73 M | 7.41 M |
| Current Assets | 8.89 M | 3.3 M | 6.88 M | 25.8 M |
| Current Liabilities | 28.58 M | 21.86 M | 19.05 M | 15.59 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -14.11 M | -10.64 M | -21.66 M | -39.76 M |
| Investing CF | -2.81 M | 0 M | -0 M | -0.01 M |
| Financing CF | 23.28 M | 7.49 M | 6.2 M | 32.21 M |
| Free CF | -14.11 M | -10.64 M | -21.66 M | -39.77 M |
| Capex | — | — | -0 M | -0.01 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 16.66% | 24.16% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-04-02 | 1:0.1 |